Back to Agenda
DA02: Current and Future Status of Drug Development in Japan, the US, and Europe under COVID-19 Pandemic
Session Chair(s)
E. Stewart Geary, MD
MD, Global Safety Officer
Eisai Co., Ltd., Japan
Junko Sato, PhD
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Gerald Dal Pan, MD, MHS
FDA, United States
Director, Office of Surveillance and Epidemiology, CDER
Peter Honig, MD, MPH, FACP
Advisor and Board Member, United States
Kiyohito Nakai, PhD
Ministry of Health, Labour and Welfare (MHLW), Japan
Director, Pharmaceutical Safty Division
Have an account?